These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 12404688)
1. Remarkable effect of milnacipran in the treatment of Japanese major depressive patients. Higuchi H; Yoshida K; Takahashi H; Naito S; Tsukamoto K; Kamata M; Ito K; Sato K; Shimizu T Hum Psychopharmacol; 2002 Jun; 17(4):195-6. PubMed ID: 12404688 [No Abstract] [Full Text] [Related]
2. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients. Higuchi H; Yoshida K; Takahashi H; Naito S; Kamata M; Ito K; Sato K; Tsukamoto K; Shimizu T; Nakanishi M; Hishikawa Y Hum Psychopharmacol; 2003 Jun; 18(4):255-9. PubMed ID: 12766929 [TBL] [Abstract][Full Text] [Related]
3. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender. Morishita S; Arita S Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720 [No Abstract] [Full Text] [Related]
4. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Yoshida K; Takahashi H; Higuchi H; Kamata M; Ito K; Sato K; Naito S; Shimizu T; Itoh K; Inoue K; Suzuki T; Nemeroff CB Am J Psychiatry; 2004 Sep; 161(9):1575-80. PubMed ID: 15337646 [TBL] [Abstract][Full Text] [Related]
5. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Tignol J; Pujol-Domenech J; Chartres JP; Léger JM; Plétan Y; Tonelli I; Tournoux A; Pezous N Acta Psychiatr Scand; 1998 Feb; 97(2):157-65. PubMed ID: 9517912 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease. Mizukami K; Hatanaka K; Tanaka Y; Sato S; Asada T Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):349-52. PubMed ID: 19166899 [TBL] [Abstract][Full Text] [Related]
7. A comparative study of milnacipran and paroxetine in outpatients with major depression. Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A; J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719 [TBL] [Abstract][Full Text] [Related]
9. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports. Takahashi H; Kamata M; Yoshida K; Higuchi H; Shimizu T Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):351-3. PubMed ID: 15694247 [TBL] [Abstract][Full Text] [Related]
10. Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report. Kito S; Nakajima T; Koga Y Eur Psychiatry; 2005 Jun; 20(4):355. PubMed ID: 16018932 [No Abstract] [Full Text] [Related]
11. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Yoshida K; Higuchi H; Takahashi H; Kamata M; Sato K; Inoue K; Suzuki T; Itoh K; Ozaki N Hum Psychopharmacol; 2008 Mar; 23(2):121-8. PubMed ID: 18023073 [TBL] [Abstract][Full Text] [Related]
12. [New drug therapy of adult attention deficit hyperactivity disorder--evaluation of efficacy of milnacipran]. Masuko H Seishin Shinkeigaku Zasshi; 2008; 110(10):908-11. PubMed ID: 19278066 [No Abstract] [Full Text] [Related]
13. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression. Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426 [TBL] [Abstract][Full Text] [Related]
14. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Puech A; Montgomery SA; Prost JF; Solles A; Briley M Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045 [TBL] [Abstract][Full Text] [Related]
15. Addition of a dopamine agonist, cabergoline, to a serotonin-noradrenalin reuptake inhibitor, milnacipran as a therapeutic option in the treatment of refractory depression: two case reports. Takahashi H; Yoshida K; Higuchi H; Shimizu T; Inoue T; Koyama T Clin Neuropharmacol; 2003; 26(5):230-2. PubMed ID: 14520161 [TBL] [Abstract][Full Text] [Related]